Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp,...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1167791/full |
| _version_ | 1797834686853021696 |
|---|---|
| author | Selina Reiter Christopher Schroeder Julian Broche Tobias Sinnberg Irina Bonzheim Daniela Süsskind Lukas Flatz Andrea Forschner |
| author_facet | Selina Reiter Christopher Schroeder Julian Broche Tobias Sinnberg Irina Bonzheim Daniela Süsskind Lukas Flatz Andrea Forschner |
| author_sort | Selina Reiter |
| collection | DOAJ |
| description | Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM. |
| first_indexed | 2024-04-09T14:42:38Z |
| format | Article |
| id | doaj.art-a89964a882e945548b25b9e0561b8872 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T14:42:38Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a89964a882e945548b25b9e0561b88722023-05-03T05:21:50ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-05-011310.3389/fonc.2023.11677911167791Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case reportSelina Reiter0Christopher Schroeder1Julian Broche2Tobias Sinnberg3Irina Bonzheim4Daniela Süsskind5Lukas Flatz6Andrea Forschner7Department of Dermatology, University Hospital of Tübingen, Tübingen, GermanyInstitute of Medical Genetics and Applied Genomics, University Hospital of Tübingen, Tübingen, GermanyInstitute of Medical Genetics and Applied Genomics, University Hospital of Tübingen, Tübingen, GermanyDepartment of Dermatology, University Hospital of Tübingen, Tübingen, GermanyInstitute of Pathology and Neuropathology, University Hospital of Tübingen, Tübingen, GermanyDepartment of Ophthalmology, University Hospital of Tübingen, Tübingen, GermanyDepartment of Dermatology, University Hospital of Tübingen, Tübingen, GermanyDepartment of Dermatology, University Hospital of Tübingen, Tübingen, GermanyMetastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM.https://www.frontiersin.org/articles/10.3389/fonc.2023.1167791/fulltebentafuspimmune checkpoint inhibitorsuveal melanomabi-specific therapyctDNA |
| spellingShingle | Selina Reiter Christopher Schroeder Julian Broche Tobias Sinnberg Irina Bonzheim Daniela Süsskind Lukas Flatz Andrea Forschner Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report Frontiers in Oncology tebentafusp immune checkpoint inhibitors uveal melanoma bi-specific therapy ctDNA |
| title | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
| title_full | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
| title_fullStr | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
| title_full_unstemmed | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
| title_short | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
| title_sort | successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp a case report |
| topic | tebentafusp immune checkpoint inhibitors uveal melanoma bi-specific therapy ctDNA |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1167791/full |
| work_keys_str_mv | AT selinareiter successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT christopherschroeder successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT julianbroche successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT tobiassinnberg successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT irinabonzheim successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT danielasusskind successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT lukasflatz successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT andreaforschner successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport |